Versor Investments LP Buys New Position in AtriCure, Inc. (NASDAQ:ATRC)

Versor Investments LP purchased a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 7,100 shares of the medical device company's stock, valued at approximately $217,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Bank of New York Mellon Corp increased its holdings in AtriCure by 2.7% during the 4th quarter. Bank of New York Mellon Corp now owns 258,272 shares of the medical device company's stock worth $7,893,000 after purchasing an additional 6,809 shares during the last quarter. Cowa LLC purchased a new stake in AtriCure during the 4th quarter worth approximately $217,000. Handelsbanken Fonder AB increased its holdings in AtriCure by 11.3% during the 4th quarter. Handelsbanken Fonder AB now owns 19,700 shares of the medical device company's stock worth $602,000 after purchasing an additional 2,000 shares during the last quarter. Alberta Investment Management Corp increased its holdings in AtriCure by 31.7% during the 4th quarter. Alberta Investment Management Corp now owns 17,603 shares of the medical device company's stock worth $538,000 after purchasing an additional 4,236 shares during the last quarter. Finally, HighMark Wealth Management LLC increased its holdings in AtriCure by 19.2% during the 4th quarter. HighMark Wealth Management LLC now owns 83,725 shares of the medical device company's stock worth $2,559,000 after purchasing an additional 13,500 shares during the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

Insider Activity at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the transaction, the director now owns 17,828 shares in the company, valued at $679,603.36. The trade was a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 3.20% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several research firms have issued reports on ATRC. Oppenheimer lifted their price objective on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a report on Thursday, February 13th. JMP Securities restated a "market outperform" rating and set a $60.00 price objective on shares of AtriCure in a report on Monday, February 10th. Needham & Company LLC restated a "buy" rating and set a $51.00 price objective on shares of AtriCure in a report on Thursday, February 13th. Canaccord Genuity Group lifted their price objective on AtriCure from $61.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Finally, Stifel Nicolaus boosted their price target on AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $51.56.

AtriCure Stock Performance

Shares of NASDAQ ATRC traded down $1.73 during trading on Friday, reaching $34.52. The stock had a trading volume of 743,589 shares, compared to its average volume of 665,876. AtriCure, Inc. has a one year low of $18.94 and a one year high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. The stock has a market cap of $1.69 billion, a PE ratio of -36.34 and a beta of 1.53. The firm's 50 day moving average price is $37.85 and its two-hundred day moving average price is $33.08.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.